caa a22 4500 445810378 CHVBK 20180317145209.0 cr unu---uuuuu 170323e20110501xx s 000 0 eng 10.1007/s00415-011-6009-x doi (NATIONALLICENCE)springer-10.1007/s00415-011-6009-x Managing MS in a changing treatment landscape [Elektronische Daten] [Martin Duddy, Aiden Haghikia, Eleonora Cocco, Christian Eggers, Jelena Drulovic, Olga Carmona, Helene Zéphir, Ralf Gold] Increasing options are dictating the development of new algorithms to provide guidance in the treatment of people with multiple sclerosis (MS). There is a wealth of evidence on the safety and efficacy of interferon-beta and glatiramer acetate, which have been used in Europe and in the United States for more than 10years. The spectrum of approved indications for these conventional disease modifying therapies includes the treatment of relapsing-remitting MS, secondary progressive MS, and the clinically isolated syndrome. Beyond these therapies we already have the recently introduced antibody natalizumab and, in some countries, the immunosuppressive agent mitoxantrone. Oral therapies are expected in the near future, with the sphingosin-1-phosphate receptor modulator fingolimod approved in the US and the EU and the purine nucleoside analogue cladribine in Australia and Russia. The evidence on all of these conventional and novel therapeutics is reviewed in this paper to provide an overview of the changing landscape of MS treatment. Springer-Verlag, 2011 Multiple sclerosis nationallicence Interferon-beta nationallicence Glatiramer acetate nationallicence Mitoxantrone nationallicence Natalizumab nationallicence Fingolimod nationallicence Cladribine nationallicence Duddy Martin Department of Neurology, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK aut Haghikia Aiden Department of Neurology, St. Josef-Hospital/Ruhr-University Bochum, Gudrunstrasse 56, 44791, Bochum, Germany aut Cocco Eleonora Multiple Sclerosis Centre, Department of Cardiovascular and Neurological Science, University of Cagliari, Cagliari, Italy aut Eggers Christian Department of Neurology, Krankenhaus der Barmherzigen Brüder, Linz, Austria aut Drulovic Jelena Clinic of Neurology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia aut Carmona Olga Neurology Department, Hospital de Figueres, Girona, Spain aut Zéphir Helene Department of Neurology, Hôpital R. Salengro, Lille, France aut Gold Ralf Department of Neurology, St. Josef-Hospital/Ruhr-University Bochum, Gudrunstrasse 56, 44791, Bochum, Germany aut Journal of Neurology Springer-Verlag 258/5(2011-05-01), 728-739 0340-5354 258:5<728 2011 258 415 https://doi.org/10.1007/s00415-011-6009-x text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00415-011-6009-x text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Duddy Martin Department of Neurology, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK aut NATIONALLICENCE 700 1- Haghikia Aiden Department of Neurology, St. Josef-Hospital/Ruhr-University Bochum, Gudrunstrasse 56, 44791, Bochum, Germany aut NATIONALLICENCE 700 1- Cocco Eleonora Multiple Sclerosis Centre, Department of Cardiovascular and Neurological Science, University of Cagliari, Cagliari, Italy aut NATIONALLICENCE 700 1- Eggers Christian Department of Neurology, Krankenhaus der Barmherzigen Brüder, Linz, Austria aut NATIONALLICENCE 700 1- Drulovic Jelena Clinic of Neurology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia aut NATIONALLICENCE 700 1- Carmona Olga Neurology Department, Hospital de Figueres, Girona, Spain aut NATIONALLICENCE 700 1- Zéphir Helene Department of Neurology, Hôpital R. Salengro, Lille, France aut NATIONALLICENCE 700 1- Gold Ralf Department of Neurology, St. Josef-Hospital/Ruhr-University Bochum, Gudrunstrasse 56, 44791, Bochum, Germany aut NATIONALLICENCE 773 0- Journal of Neurology Springer-Verlag 258/5(2011-05-01), 728-739 0340-5354 258:5<728 2011 258 415 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer